Showing results (1-10 of 12) with videos related to
Sort By:
Pageof 2
Leukemia|April 6, 2013
An evolutionary perspective on chronic myelomonocytic leukemiaR Itzykson, E SolaryLeukemia|March 8, 2008
Meeting report: myelodysplastic syndromes at ASH 2007R Itzykson, C Gardin, P FenauxLeukemia|April 4, 2014
ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patientsM M Patnaik, R Itzykson, T L Lasho, et al.Blood Cancer Journal|January 3, 2015
Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcomeM M Patnaik, E A Wassie, E Padron, et al.Leukemia|April 16, 2011
Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemiasR Itzykson, O Kosmider, T Cluzeau, et al.Leukemia Research|December 20, 2011
Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?R Itzykson, S Thépot, O Beyne-Rauzy, et al.Leukemia Research|January 21, 2015
Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome predictionF Ramos, S Thépot, L Pleyer, et al.Leukemia|February 2, 2013
Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agentsC Kelaidi, S Park, R Sapena, et al.Leukemia|January 20, 2009
Is there a role for all-trans retinoic acid in combination with recombinant erythropoetin in myelodysplastic syndromes? A report on 59 casesR Itzykson, S Ayari, D Vassilief, et al.Pageof 2